ClinicalTrials.gg
CompletedNCT03445221Updated Aug 16, 2022

Preoperative Immunonutrition and Cardiac Patients

A Phase 2/3 interventional study of IV Immunonutrition and Conventional Diet in Cardiac Function, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-08-16.

Sponsored by Assiut University · Phase 2/3, Interventional, and Prevention

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

With the progress of cardiac surgery, the indication of cardiac valve replacement has been extended to include severely ill patients, even those with cardiac cachexia caused by long-standing mitral valve disease. Since patients with advanced cardiac functional disability are prone to fall into a low cardiac output state after valve replacement, Those severely ill, cachectic patients may be susceptible to postoperative acute renal failure. Preoperative malnutrition because of poor oral intake significantly increases the risk of adverse events after surgery and leads to increased length of stay.

Major operation itself possibly cause the dysfunction of the host homeostasis, defense mechanisms and inflammatory response, which would increase the rate of postoperative complications and prolong hospital stay. Recently, many researchers argued that immunonutritional formulas supplemented with biologically active nutrients were more effective than standard nutrition intervention in improving inflammation, promoting the wound healing and shortening the length of hospital stay (LOS) after operation.

Read the detailed description

Eligibility and type of the study: This randomized clinical trial will be conducted at Assiut University Hospital from March 2018 until March 2019 after approval from the Institutional Ethics Committee and after obtaining written informed consents from all cardiac patients undergoing mitral valve replacement surgery.

Randomization and sample size :

Sample size calculation Sample size calculation was carried out using G*Power 3 software. A calculated sample of 88 patients (44 cases and 44 controls) will be needed to detect an effect size of 0.3 reduction in pro-BNP Level, with an error probability of 0.05 and 90% power on a two-tailed test.

Patients:

Patients will be assigned into two equal groups of 44 patients each:

Group 1: patients will take preoperative immunonutrition in the form of intravenous glutamine (Dipeptiven-Fersenius Kabi) 0.4 g/kg/day (once daily) for 5 days before surgery in addition to a conventional diet.

Group 2: patients will continue conventional diet. Conventional median sternotomy will be performed in all patients. Arterial line will be inserted. Anesthesia will be induced with midazolam 0.05mg\kg, propofol 1-1.5mg\kg and fentanyl 2μg\kg. Anesthesia will be maintained with isoflurane, fentanyl infusion1-2μ\kg\hr and Cis-atracurium infusion 2μ\kg\min before cardiopulmonary bypass (CBP) and with propofol and fentanyl on CBP, according the anaesthetist criteria. Anticoagulation will be achieved with heparin 3-4 mg\kg to maintain an activated clotting time over 450s .Reversal of heparin will be with protamine. Cardiopulmonary bypass will be achieved with a roller pump and a membrane oxygenator. After the aortic clamp will be applied, asolution of 1000-1500 cc of hematic cardioplegia will be administrated. Then 400-500 cc of solution will be administrated every 30min until the end of the procedure. Mean arterial pressure should be above 60 mmHg for the duration of CBP.

Data collection:

Cardiac function:

  • Preoperative and postoperative echocardiography.
  • Inotropic score every 2hours in first 6 hours then every 6 hours for the rest of 48 hours postoperatively.
  • Serum proBNP (Brain natruritic peptide) preoperatively and post operative first and forth days.

Kidney function:

  • Urine output in the postoperative first and second days.
  • Serum urea and creatinine in postoperative first and second days.
  • Serum NGAL (Neutrophil gelatinase-associated lipocalin) preoperatively and postoperative first and forth days.

Hemodynamics:

- MAP, HR every 2hours in first 6 hours then every 6 hours for the rest of 48 hours postoperatively.

Hours of mechanical ventilation. Hospital and ICU stay. Any postoperative complications will be recorded and treated.

Sampling:

Venous blood sample will be obtained by direct venipuncture and collected into serum separator tubes. Samples will be centrifuged within 20 minutes from withdrawal and stored for amixture of 12 hours at 2-8 ゜C before the separation of serum. Serum will be stored frozen at -40 ゜C. Pro-BNP serum concentrations will be determined using an automated method.

Statistical analysis :

Data will be performed using a standard SPSS software package version 21 (SPSS Inc., Chicago, Illinois, USA).Descriptive values will be expressed as mean ± SD, number or percentages. The Student t-test will be used for comparison between means of variables and normally distributed data. P will be considered significant if (p≤ 0.05).

Ethical Consideration:

  • The randomized clinical trial will be approved by local ethics committee of faculty of medicine, Assiut University, Egypt after obtaining written informed consent from patients.
  • There is no risk affecting the patients participating in this study.
  • Every patient can leave the study and will receive the same care.
  • Any data taken from all patient will be made confidential and available only to persons conducting the study.
  • Any patient can stop participation in the study at any time without any loss of service.
02

Conditions studied

  • Cardiac Function

Keywords

  • Immunonutrition
  • Cardiac Patient
  • Mitral Valve Replacement
03

In context

Lead sponsor

Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both sex
  • Age: 18-60 years.
  • Valvular heart disease .
  • ASA II,III
  • Non-diabetic.
  • Elective surgery.

Exclusion criteria

Exclusion Criteria:

  • Pre-existing renal disease(creatinine3.5mg/dl or dialysis)
  • Diabetic.
  • Off pump surgery.
  • Long CBP time >120 min .
  • Previous cardiac surgery.
  • Hepatic failure or established cirrhosis.
  • Emergency surgery
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Group I

    Patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.

    Dietary Supplement: IV Immunonutrition

  • Active comparator
    Group II

    Patients will continue preoperative oral conventional diet.

    Dietary Supplement: Conventional Diet

Interventions

  • Dietary supplementIV Immunonutrition

    patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.

  • Dietary supplementConventional Diet

    patients will continue preoperative oral conventional diet.

06

What researchers measure

Primary outcomes

  1. Cardiac Fuction

    Serum proBNP (Brain natruritic peptide)

    Time frame: 4 days

Secondary outcomes

  1. Inotropic score

    Dopamine dose (mcg/kg/min) + Dobutamine dose (mcg/kg/min) + 100 x Epinephrine dose (mcg/kg/min) min 20 and max 60 The lower the inotropic score the better cardiac function and lower morbidity

    Time frame: 4 days

  2. Kidney Function

    Serum NGAL (Neutrophil gelatinase-associated lipocalin)

    Time frame: 4 days

  3. urine output

    urine volume per day

    Time frame: 2 days

  4. Hemodynamics

    mean arterial blood pressure

    Time frame: 2 days

  5. Postoperative Hospital Data

    Hospital and ICU stay

    Time frame: 4 days

  6. Postoperative complications

    any postoperative complications

    Time frame: 4 days

07

Study locations

1 site
  • Assiut university hospital
    Asyut, 71515, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03445221
Lead sponsor
Assiut University
Responsible party
Mohamed F. Mostafa (Associate Professor of Anesthesia and Intensive Care, Assiut University) — Principal investigator
First posted
Feb 26, 2018
Start date
Aug 1, 2018
Primary completion
Mar 31, 2022
Completion
Mar 31, 2022
Last update
Aug 16, 2022

Study contacts

Khaled M Morsy, MD
study director · Assistant prof of anesthesia and intensive care

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion